Amanta Healthcare Files Draft Papers with SEBI for IPO: Key Details and Insights

Amanta Healthcare IPO Overview

Amanta Healthcare, a prominent pharma company, has filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise funds through an initial public offering (IPO). The Amanta Healthcare IPO size is projected at up to 1,25,00,000 equity shares, with a face value of ₹10 each, all issued as a fresh issue.

Funding Objectives and Utilization

Amanta aims to utilize the raised funds for capital expenditure requirements crucial for civil construction work, alongside purchasing equipment, plant, and machinery for a new manufacturing line, specifically for SteriPort at Hariyala, Kheda, Gujarat. The company also targets funding for a new Small Volume Parenteral (SVP) manufacturing line to expand its operational capability and strengthen product offerings.

Company Profile and Manufacturing Expertise

Amanta Healthcare Limited specializes in the development, manufacturing, and marketing of sterile liquid products. Utilizing advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), Amanta produces rapid drug absorption parenteral solutions for patients unable to take oral medications.

• Manufactures large and small volume parenterals (LVPs and SVPs)
• Operates across six therapeutic segments including fluid therapy and respiratory care
• Complies with global GMP standards, exporting to 19 countries
• Maintains 113 active international product registrations

Other Companies in the Space

In addition to Amanta Healthcare, others like All Time Plastics, Scoda Tubes, and Dev Accelerator (DevX) have also submitted draft red herring prospectuses (DRHPs) to SEBI for their upcoming IPOs.